<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="../../css/uswds.min.css">
    <link rel="stylesheet" href="../../css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="../../index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="../../index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="../titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="../parts/21CFR312.html">Part 312
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 312.310  Individual patients, including for emergency use.
                            </h3>
                            <p class="depth0">Under this section, FDA may permit an investigational drug to be  used for the treatment of an individual patient by a licensed physician.</p><p class="depth1"><em>(a)</em> must be met; and the  following determinations must be made:</p><p class="depth2"><em>(1)</em> The physician must determine that the probable risk to the  person   from the investigational drug is not greater than the probable risk from  the disease or condition; and</p><p class="depth2"><em>(2)</em> FDA must determine that the patient cannot obtain the drug under  another IND or protocol.</p><p class="depth1"><em>(b)</em>.</p><p class="depth2"><em>(1)</em> If the drug is the subject of an existing IND, the expanded  access submission may be made by the sponsor or by a licensed physician.</p><p class="depth2"><em>(2)</em> A sponsor may satisfy the submission requirements by amending  its existing IND to include a protocol for individual patient expanded  access.</p><p class="depth2"><em>(3)</em> A licensed physician may satisfy the submission requirements by  obtaining from the sponsor permission for FDA to refer to any  information in the IND that would be needed to support the expanded  access request (right of reference) and by providing any other required  information not contained in the IND (usually only the information  specific to the individual patient).</p><p class="depth1"><em>(c)</em> Safeguards. </p><p class="depth2"><em>(1)</em> Treatment is generally limited to a single  course of therapy for a specified duration unless FDA expressly  authorizes multiple courses or chronic therapy.</p><p class="depth2"><em>(2)</em> At the conclusion of treatment, the licensed physician or  sponsor must provide FDA with a written summary of the results of the  expanded access use, including adverse effects.</p><p class="depth2"><em>(3)</em> FDA may require sponsors to monitor an individual patient  expanded access use if the use is for an extended duration.</p><p class="depth2"><em>(4)</em> When a significant number of similar individual patient expanded  access requests have been submitted, FDA may ask the sponsor to submit  an IND or protocol for the use under Sec. 312.315 or Sec. 312.320.</p><p class="depth1"><em>(d)</em> Emergency procedures. If there is an emergency that requires the  patient to be treated before a written submission can be made, FDA may  authorize the expanded access use to begin without a written submission.  The FDA reviewing official may authorize the emergency use by telephone.</p><p class="depth2"><em>(1)</em> Emergency expanded access use may be requested by telephone,  facsimile, or other means of electronic communications. For  investigational biological drug products regulated by the Center for  Biologics Evaluation and Research, the request should be directed to the  Office of Communication, Outreach and Development, Center for Biologics  Evaluation and Research, 301-827-1800 or 1-800-835-4709, e-mail:  ocod@fda.hhs.gov. For all other investigational drugs, the request for  authorization should be directed to the Division of Drug Information,  Center for Drug Evaluation and Research, 301-796-3400, e-mail:  druginfo@fda.hhs.gov. After normal working hours (8 a.m. to 4:30 p.m.),  the request should be directed to the FDA Emergency Call Center, 866- 300-4374, e-mail: emergency.operations@fda.hhs.gov.</p><p class="depth2"><em>(2)</em> The licensed physician or sponsor must explain how the expanded  access use will meet the requirements of Sec. Sec. 312.305 and 312.310  and must agree to submit an expanded access submission within 15 working  days of FDA's authorization of the use.  [74 FR 40942, Aug. 13, 2009, as amended at 75 FR 32659, June 9, 2010]</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§ by <a href="https://18f.gsa.gov/">18F</a>.
          Code available <a href="https://github.com/18F/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5>
      </div>
    </div>
  </footer>
  </body>
</html>
